# Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function

> **NCT01563562** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 34 (actual)

## Conditions studied

- Hepatic Impairment
- Healthy

## Interventions

- **DRUG:** Bardoxolone Methyl

## Key facts

- **NCT ID:** NCT01563562
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-30
- **Primary completion:** 2012-11-30
- **Final completion:** 2012-11-30
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01563562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01563562, "Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01563562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*